SOLICITATION NOTICE
66 -- Notice of Intent to Sole Source Seahorse XFPro Analyzer
- Notice Date
- 8/29/2022 7:32:18 AM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95022Q00291
- Response Due
- 8/31/2022 8:00:00 AM
- Archive Date
- 09/15/2022
- Point of Contact
- Alexander Beraud, Phone: 3014436677, Josh Lazarus, Phone: 3014436677
- E-Mail Address
-
alexander.beraud@nih.gov, josh.lazarus@nih.gov
(alexander.beraud@nih.gov, josh.lazarus@nih.gov)
- Description
- DESCRIPTION OF REQUIREMENT PURPOSE AND OBJECTIVES: The purpose of this requirement is to provide the National Institute of Neurological Disorders and Stroke (NINDS), Inherited Movement Disorders Unit (IMDU) laboratory a Seahorse XFPro Analyzer. The IMDU focuses on mitochondrial dysfunction in genetic forms of Parkinson�s disease. To date, the IMDU researchers have investigated the roles of specific mitochondrial proteins (including Parkin, PINK1, CHCHD2, and CHCHD10) which cause neurodegeneration when mutated. To assess mitochondrial dysfunction in cellular and mouse models of these diseases, the researchers have been using the Seahorse XFp Analyzer to measure basal and maximal oxygen consumption in cultured cells as well as extracellular acidification. This instrument, however, can compare only 2 conditions in technical triplicate at a time. This purchase is to upgrade to an instrument that allows analysis of up to 96 samples allowing for the needed comparison of mitochondrial function in multiple conditions at a time. The objective of this acquisition is to provide NINDS, IMDU laboratory a Seahorse XFPro Analyzer.to support and preserve the integrity of and access to the data previously collected and necessary for continuity of use of proprietary software and instruments already in use in the IMDU lab. PROJECT REQUIREMENTS: Seahorse XFPro Analyzer (64-bit) Salient Characteristics 1.������� Ability to analyze oxygen consumption in 10,000 intact cells or less 2.������� Ability to analyze glycosis in 10,000 cells or less 3.������� Ability to measure oxygen consumption in 5 ug of isolated mitochondria or less 4.������� Ability to process at least 96 samples at a time 5.������� Device with small enough foot print and stability on a benchtop 6.������� Integrated normalization of cell number in analyzed well normalized by cell count 7.������� Data must be directly comparable to those generated by the lab�s existing Seahorse XFp instrument for continuation of an ongoing project Delivery: 35 Convent Drive, Room 2A213 Bethesda, MD 20852 CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Agilent Technologies is the only entity that manufactures the upgraded equipment, Seahorse XFPro Analyzer, which is necessary to preserve the integrity of and access to the data previously collected and is necessary for continuity of use of proprietary software and instruments already in use in the lab. Because this request is to upgrade to an instrument that allows analysis of up to 96 samples to compare mitochondrial function in multiple conditions at a time, there is currently only one commercial source available: Agilent Technologies. The intended source is: Agilent Technologies 5301 Stevens Creek Blvd Santa Clara, CA, 95051 Ph: 1-800-227-9770 Lscainstrumentsales@agilent.com United States of America PLEASE SEE THE ATTACHED NOTICE OF INTENT TO SOLE SOURCE FOR ALL RELEVANT DETAILS
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/3cdfeddc0d684ce899d1fb966375bc92/view)
- Place of Performance
- Address: Bethesda, MD, USA
- Country: USA
- Country: USA
- Record
- SN06445125-F 20220831/220829230132 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |